{"generic":"Aminohippurate Sodium","drugs":["Aminohippurate Sodium"],"mono":{"0":{"id":"24990-s-0","title":"Generic Names","mono":"Aminohippurate Sodium"},"1":{"id":"24990-s-1","title":"Dosing and Indications","sub":{"0":{"id":"24990-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>para-Aminohippurate renal clearance measurement:<\/b> priming dose, 6 to 10 mg\/kg IV<\/li><li><b>para-Aminohippurate renal clearance measurement:<\/b> infusion dose, 10 to 24 mg\/min IV<\/li><li><b>para-Aminohippurate renal clearance measurement:<\/b> optimal concentration of aminohippurate sodium in plasma is 2 mg per 100 mL<\/li><li><b>para-Aminohippurate renal clearance measurement:<\/b> normal ERPF values are 675 +\/- 150 mL\/min (men) and 595 +\/- 125 mL\/min (women)<\/li><li><b>Renal tubular disorder; Diagnosis:<\/b> usual concentration range, 40 to 60 mg per 100 mL in order to sufficiently saturate the capacity of the tubular secretory cells<\/li><\/ul>"},"1":{"id":"24990-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness in pediatric patients not established "},"3":{"id":"24990-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>para-Aminohippurate renal clearance measurement<\/li><li>Renal tubular disorder; Diagnosis<\/li><\/ul>"}}},"3":{"id":"24990-s-3","title":"Contraindications\/Warnings","sub":[{"id":"24990-s-3-9","title":"Contraindications","mono":"hypersensitivity to aminohippurate sodium or any component of the product <br\/>"},{"id":"24990-s-3-10","title":"Precautions","mono":"<ul><li>adverse reactions may occur; administer IV slowly; monitoring recommended<\/li><li>concomitant use of probenecid; may result in erroneously low effective renal plasma flow (ERPF) and the functional capacity of the renal tubular secretory mechanism or transport maximum (Tm(PAH)) values<\/li><li>concomitant use of procaine, sulfonamides, or thiazolsulfone; accuracy of results are compromised due to interference with chemical color development<\/li><li>latex sensitivity; vial stopper contains dry natural rubber that may cause allergic reactions<\/li><li>low cardiac reserve; rapid increase in plasma volume may precipitate congestive heart failure<\/li><\/ul>"},{"id":"24990-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"24990-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"24990-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Defecation urgency<\/li><li><b>Renal:<\/b>Urgent desire to urinate<\/li><li><b>Other:<\/b>Feels warm<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Hypersensitivity reaction<br\/>"},"6":{"id":"24990-s-6","title":"Drug Name Info","sub":{"2":{"id":"24990-s-6-19","title":"Class","mono":"Diagnostic Agent, Kidney Function<br\/>"},"3":{"id":"24990-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"24990-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"24990-s-7","title":"Mechanism Of Action","mono":"Since aminohippurate sodium has a high renal clearance rate (90% of administered dose is cleared by the kidneys in a single circulation), plasma and urine aminohippurate sodium concentrations are used in a calculation to determine the effective renal plasma flow, and the functional capacity of the renal tubular secretory mechanism or transport maximum (Tm(PAH)).<br\/>"},"8":{"id":"24990-s-8","title":"Pharmacokinetics","sub":{"3":{"id":"24990-s-8-26","title":"Excretion","mono":"Renal: 90% (at aminohippurate sodium plasma concentrations of 1 to 2 mg\/100 mL)<br\/>"}}},"9":{"id":"24990-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>efficacy not affected by discoloration within normal color range (ie, colorless to yellow\/brown)<\/li><li>for IV use only<\/li><\/ul>"},"10":{"id":"24990-s-10","title":"Monitoring","mono":"<ul><li>accurate measurements of the effective renal plasma flow (ERPF) and the functional capacity of the renal tubular secretory mechanism or transport maximum (Tm(PAH)) are indicative of efficacy<\/li><li>adverse effects; continuously during IV administration<\/li><\/ul>"},"11":{"id":"24990-s-11","title":"How Supplied","mono":"<b>Generic<\/b><br\/>Intravenous Solution: 20 %<br\/>"}}}